Ibuned: Uses, Dosage & Side Effects
A non-steroidal anti-inflammatory drug (NSAID) available as 200 mg film-coated tablets for the relief of pain, inflammation, and fever
Ibuned is a non-steroidal anti-inflammatory drug (NSAID) available as 200 mg film-coated tablets. It belongs to the class of medications that work by inhibiting cyclooxygenase (COX) enzymes, thereby reducing the production of prostaglandins – chemical messengers responsible for pain, inflammation, and fever. Ibuned is prescribed for the symptomatic relief of mild to moderate pain, including musculoskeletal pain, dental pain, headache, menstrual cramps, and post-operative pain. It is also used to manage inflammatory conditions such as osteoarthritis and rheumatoid arthritis. As a prescription medication, Ibuned should be used at the lowest effective dose for the shortest duration necessary to control symptoms, in accordance with current international NSAID safety guidelines.
Quick Facts: Ibuned
Key Takeaways
- Ibuned is an NSAID prescribed as 200 mg film-coated tablets for the relief of mild to moderate pain, fever, and inflammation associated with conditions such as osteoarthritis, rheumatoid arthritis, dental pain, headaches, and menstrual cramps.
- It works by inhibiting cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, which decreases pain signalling, inflammatory responses, and elevated body temperature.
- All NSAIDs, including Ibuned, carry risks of serious gastrointestinal events (bleeding, ulceration, perforation) and cardiovascular thrombotic events – the lowest effective dose should be used for the shortest duration needed.
- Ibuned should not be taken by individuals with active peptic ulcers, severe heart/liver/kidney failure, a history of NSAID-triggered asthma or allergic reactions, or during the third trimester of pregnancy.
- Important drug interactions exist with anticoagulants, aspirin, ACE inhibitors, lithium, methotrexate, SSRIs, corticosteroids, and diuretics – always inform your doctor of all medications you are taking.
What Is Ibuned and What Is It Used For?
Ibuned belongs to the non-steroidal anti-inflammatory drug (NSAID) class of medications. NSAIDs are among the most widely prescribed and used medications worldwide, recognized by the World Health Organization (WHO) as essential medicines for managing pain and inflammation. Ibuned is formulated as a 200 mg film-coated tablet designed for oral administration. The film coating helps protect the stomach lining during the initial passage through the gastrointestinal tract and makes the tablet easier to swallow.
The primary mechanism of action of Ibuned involves the inhibition of cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. These enzymes play a central role in the arachidonic acid pathway, catalysing the conversion of arachidonic acid to prostaglandins, thromboxanes, and prostacyclins. Prostaglandins are lipid compounds that act as local chemical messengers in the body. At sites of tissue injury or inflammation, prostaglandins sensitise nerve endings to pain, promote vasodilation, increase vascular permeability, and contribute to the classic signs of inflammation: redness, heat, swelling, and pain. By reducing prostaglandin synthesis, Ibuned provides three distinct therapeutic effects: analgesia (pain relief), anti-inflammatory action (reduction of swelling and inflammation), and antipyretic activity (fever reduction).
Ibuned is prescribed for a variety of conditions where pain, inflammation, or fever are prominent features. The drug is commonly used for the symptomatic treatment of the following conditions:
- Musculoskeletal pain: Including back pain, sprains, strains, sports injuries, and soft tissue inflammation. Ibuned helps reduce both pain and the associated inflammatory response, supporting recovery and improved mobility.
- Osteoarthritis (OA): A degenerative joint disease characterised by cartilage breakdown, leading to joint pain, stiffness, and reduced function. Ibuned helps manage the pain and inflammation associated with osteoarthritis, particularly during flare-ups, and can improve daily function and quality of life.
- Rheumatoid arthritis (RA): A chronic autoimmune inflammatory condition affecting the joints. NSAIDs like Ibuned are commonly used alongside disease-modifying antirheumatic drugs (DMARDs) to provide symptomatic relief of joint pain and morning stiffness.
- Dental pain: Post-extraction pain, toothache, and pain following dental procedures. NSAIDs are considered first-line analgesics for acute dental pain by many clinical guidelines.
- Headache and migraine: Mild to moderate tension-type headaches and migraine attacks. NSAIDs are recommended as initial therapy for acute migraine by the European Headache Federation and other international guidelines.
- Dysmenorrhoea (menstrual pain): Primary menstrual cramps caused by excessive prostaglandin production in the uterine lining. NSAIDs are first-line therapy for primary dysmenorrhoea because they directly target the underlying prostaglandin-mediated mechanism.
- Post-operative pain: Mild to moderate pain following surgical procedures. Ibuned may be used alone or as part of a multimodal analgesic regimen to reduce opioid requirements.
- Fever: Ibuned lowers elevated body temperature by acting on the hypothalamic thermoregulatory centre, reducing the prostaglandin E2 (PGE2) that drives the febrile response.
After oral administration, Ibuned is well absorbed from the gastrointestinal tract. Peak plasma concentrations are typically reached within 1 to 2 hours after ingestion, although this may be delayed if taken with food. The drug is extensively bound to plasma proteins (approximately 99%) and is distributed throughout the body, including to inflamed joints where it exerts its therapeutic effect. Metabolism occurs primarily in the liver via cytochrome P450 enzymes (predominantly CYP2C9), producing inactive metabolites that are excreted mainly through the kidneys. The elimination half-life is approximately 2 to 4 hours, which means that multiple daily doses are usually required to maintain therapeutic drug levels throughout the day.
International guidelines, including those from the European Medicines Agency (EMA), the FDA, and NICE, consistently recommend using NSAIDs at the lowest effective dose for the shortest duration necessary to control symptoms. This approach minimises the risk of gastrointestinal, cardiovascular, and renal adverse effects while still providing adequate pain relief and anti-inflammatory activity. Your doctor will determine the most appropriate dose and duration for your specific condition.
What Should You Know Before Taking Ibuned?
Contraindications
There are specific situations in which Ibuned must not be used. Understanding these contraindications is essential for safe use of this medication.
- Hypersensitivity: Do not take Ibuned if you are allergic to the active substance ibuned, or to any of the excipients in the tablet. Also avoid if you have previously experienced asthma, urticaria (hives), angioedema, or rhinitis triggered by aspirin or other NSAIDs. NSAID-triggered bronchospasm can be severe and potentially life-threatening.
- Active peptic ulcer disease or gastrointestinal bleeding: Ibuned must not be used if you have an active stomach or duodenal ulcer, or if you have experienced gastrointestinal bleeding or perforation related to previous NSAID therapy. A history of two or more distinct episodes of proven ulceration or bleeding also constitutes a contraindication.
- Severe heart failure: NSAIDs can worsen heart failure by promoting fluid retention, increasing blood pressure, and counteracting the effects of diuretics and ACE inhibitors. Ibuned is contraindicated in patients with severe heart failure (NYHA Class IV).
- Severe hepatic impairment: Patients with severe liver disease should not take Ibuned, as impaired hepatic metabolism can lead to drug accumulation and increased toxicity.
- Severe renal impairment: Ibuned is contraindicated in patients with severe kidney failure (GFR <30 mL/min), as prostaglandins play a critical role in maintaining renal blood flow, and their inhibition can precipitate acute kidney injury.
- Third trimester of pregnancy: NSAIDs are contraindicated from gestational week 20 onwards due to the risk of premature closure of the ductus arteriosus, oligohydramnios (reduced amniotic fluid), and fetal renal dysfunction.
- Cerebrovascular or other active bleeding: Do not use Ibuned if you have active bleeding, including cerebrovascular haemorrhage.
- Inflammatory bowel disease: Patients with active Crohn’s disease or ulcerative colitis should avoid NSAIDs, as they can trigger flare-ups of these conditions.
Warnings and Precautions
NSAIDs, including Ibuned, may increase the risk of serious cardiovascular thrombotic events (heart attack and stroke), especially with long-term use or in patients with existing cardiovascular disease or risk factors. They also increase the risk of serious gastrointestinal events including bleeding, ulceration, and perforation, which can be fatal and can occur at any time during use, with or without warning symptoms. Elderly patients are at higher risk for both types of events.
Before and during treatment with Ibuned, discuss the following with your doctor:
- Cardiovascular disease: Patients with a history of hypertension, heart disease, stroke, or peripheral arterial disease should use Ibuned with caution. Clinical studies suggest that high-dose, long-term NSAID use is associated with a small but meaningful increase in the risk of arterial thrombotic events. Blood pressure should be monitored regularly during treatment.
- Gastrointestinal risk: The risk of GI bleeding, ulceration, or perforation increases with higher doses, longer duration of NSAID use, advancing age, history of peptic ulcer disease, and concurrent use of anticoagulants, oral corticosteroids, SSRIs, or aspirin. Your doctor may prescribe a gastroprotective agent (such as a proton pump inhibitor) to reduce this risk.
- Renal function: NSAIDs can reduce renal blood flow by inhibiting prostaglandin-mediated vasodilation in the kidneys. This is particularly important in patients with pre-existing kidney disease, heart failure, liver cirrhosis, those taking diuretics or ACE inhibitors, and elderly patients. Renal function should be monitored, especially at the start of treatment and during dose adjustments.
- Hepatic effects: Elevations of liver enzymes (ALT, AST) can occur during NSAID therapy. If you develop signs of liver dysfunction (jaundice, dark urine, fatigue, nausea), discontinue Ibuned and contact your doctor.
- Asthma: Approximately 10–20% of people with asthma may have aspirin-exacerbated respiratory disease (AERD), in which NSAIDs trigger severe bronchospasm. If you have asthma, particularly if it is associated with nasal polyps, use Ibuned only under close medical supervision.
- Elderly patients: Older adults are at increased risk of NSAID-related adverse effects, particularly gastrointestinal bleeding and cardiovascular events. The lowest effective dose should be used, and regular monitoring is recommended.
- Fluid retention and oedema: NSAIDs can cause fluid retention and peripheral oedema. Use with caution in patients with heart failure or hypertension.
- Skin reactions: Rarely, serious and potentially fatal skin reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported with NSAIDs. Discontinue Ibuned at the first appearance of skin rash, mucosal lesions, or other signs of hypersensitivity.
- Fertility: NSAIDs may impair female fertility by inhibiting ovulation. This effect is reversible upon discontinuation. Women who are having difficulty conceiving or who are undergoing fertility investigations should consider stopping Ibuned.
Pregnancy and Breastfeeding
Ibuned should be avoided during the third trimester of pregnancy. From gestational week 20 onwards, NSAIDs can cause premature closure of the fetal ductus arteriosus, oligohydramnios (low amniotic fluid), and fetal kidney dysfunction. During the first and second trimesters, Ibuned should only be used if the potential benefit justifies the potential risk to the fetus, and at the lowest effective dose for the shortest possible duration. Animal studies have suggested that NSAIDs may interfere with implantation, and their use around the time of conception is generally not recommended.
Small amounts of NSAIDs can pass into breast milk. However, at therapeutic doses, the amount reaching the infant is generally considered negligible. Short-term use of Ibuned during breastfeeding is usually acceptable if recommended by your doctor, but you should discuss the benefits and risks. If long-term use is needed, consider alternative pain management strategies or temporarily discontinue breastfeeding during treatment.
Driving and Operating Machinery
Ibuned may occasionally cause dizziness, drowsiness, fatigue, or visual disturbances, particularly at higher doses. If you experience any of these effects, do not drive or operate machinery until the symptoms have resolved. Most patients can drive safely while taking Ibuned at standard doses, but individual responses vary.
How Does Ibuned Interact with Other Drugs?
Drug interactions with NSAIDs like Ibuned are clinically important because they can either increase the risk of adverse effects or reduce the effectiveness of co-administered medications. The interactions primarily involve the effects of prostaglandin inhibition on various organ systems, as well as pharmacokinetic interactions affecting drug metabolism and excretion. It is essential to inform your doctor, pharmacist, or other healthcare provider about all medications, supplements, and herbal products you are taking before starting Ibuned.
Major Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Other NSAIDs (including aspirin at anti-inflammatory doses) | Increased risk of GI bleeding and ulceration without additional therapeutic benefit | Avoid combination; do not take two NSAIDs concurrently |
| Anticoagulants (warfarin, heparin, DOACs) | Increased risk of bleeding due to impaired platelet function and GI mucosal damage | Avoid if possible; if necessary, monitor INR closely and watch for signs of bleeding |
| Lithium | Reduced renal clearance of lithium, leading to increased serum levels and risk of toxicity | Monitor lithium levels closely; dose reduction may be needed |
| Methotrexate (high-dose) | Decreased methotrexate clearance, increased risk of haematological and GI toxicity | Avoid NSAIDs within 24 hours of high-dose methotrexate; use with caution at low doses |
| ACE inhibitors / ARBs | Reduced antihypertensive effect; increased risk of renal impairment and hyperkalaemia | Monitor blood pressure and renal function; ensure adequate hydration |
Minor Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| SSRIs (e.g., fluoxetine, sertraline) | Increased risk of GI bleeding (SSRIs impair platelet serotonin uptake) | Consider gastroprotection with a PPI if combined use is necessary |
| Corticosteroids (e.g., prednisolone) | Increased risk of gastrointestinal ulceration and bleeding | Use with caution; consider gastroprotective therapy |
| Diuretics (thiazides, loop diuretics) | Reduced diuretic and antihypertensive effect; increased risk of nephrotoxicity | Monitor fluid balance, renal function, and blood pressure |
| Low-dose aspirin (cardioprotective, 75–100 mg) | Ibuned may reduce the antiplatelet effect of low-dose aspirin | Take aspirin at least 30 minutes before or 8 hours after Ibuned to preserve cardioprotection |
| Ciclosporin / Tacrolimus | Increased risk of nephrotoxicity | Monitor renal function closely during combination therapy |
| Quinolone antibiotics | Possible increased risk of convulsions | Use with caution, especially in patients with epilepsy or history of seizures |
The interaction between NSAIDs and low-dose aspirin is particularly important for patients taking aspirin for cardiovascular protection. Studies have shown that certain NSAIDs, when taken before aspirin, can compete for the same binding site on the COX-1 enzyme in platelets, effectively blocking aspirin from exerting its irreversible antiplatelet effect. To avoid this interaction, the FDA and other regulatory agencies recommend taking low-dose aspirin at least 30 minutes before or at least 8 hours after Ibuned. Your doctor can advise you on the optimal timing of these medications.
What Is the Correct Dosage of Ibuned?
The dosage of Ibuned should be individualised based on the severity of symptoms, the condition being treated, and the patient’s overall health status. The general principle is to use the lowest effective dose for the shortest duration that provides adequate symptom control. Your doctor will determine the most appropriate dose for your specific situation. The following dosing information serves as a general guide.
Adults
Mild to Moderate Pain and Fever
Initial dose: 200–400 mg (1–2 tablets)
Maintenance: 200–400 mg every 6–8 hours as needed
Maximum daily dose: 1200 mg (6 tablets) for self-medication; up to 2400 mg under medical supervision for inflammatory conditions
Administration: Take with or immediately after food with a full glass of water. Swallow the film-coated tablet whole; do not crush, chew, or break it.
Osteoarthritis and Rheumatoid Arthritis
Dose: 400–800 mg two to three times daily, as prescribed by your doctor
Maximum daily dose: Up to 2400 mg under medical supervision
Duration: Long-term use should be regularly reviewed by your doctor. Periodic assessment of the need for continued treatment, the lowest effective dose, and potential adverse effects is recommended.
Dysmenorrhoea (Menstrual Pain)
Dose: 200–400 mg every 6–8 hours
Maximum daily dose: 1200 mg
Timing: Treatment is most effective when started at the earliest onset of symptoms or pain, ideally at the beginning of menstruation. Continue for the duration of symptoms, typically 2–3 days.
Children
Ibuned 200 mg film-coated tablets are intended for adult use. For children and adolescents, the dose of NSAID-based medications must be carefully calculated based on body weight, and paediatric formulations (such as liquid suspensions) are generally preferred for younger patients. Do not give Ibuned tablets to children without specific advice from a doctor. In general, paediatric NSAID dosing follows the principle of 5–10 mg/kg per dose, given every 6–8 hours, with a maximum of 3 doses in 24 hours. Your paediatrician will advise on the appropriate formulation and dosage.
Elderly
Elderly patients (aged 65 years and over) are at increased risk of NSAID-related adverse effects, particularly gastrointestinal bleeding, cardiovascular events, and renal impairment. The lowest effective dose should be used for the shortest possible duration. Your doctor may recommend starting at a lower dose (e.g., 200 mg two to three times daily) and prescribe a gastroprotective agent such as a proton pump inhibitor (PPI) to reduce the risk of gastrointestinal complications. Regular monitoring of renal function, blood pressure, and symptoms of GI bleeding is recommended.
Missed Dose
If you forget to take a dose of Ibuned, take it as soon as you remember – unless it is almost time for your next scheduled dose. In that case, skip the missed dose and take the next one at the usual time. Do not take a double dose to make up for the one you missed. If you are taking Ibuned regularly for a chronic condition, try to take your doses at evenly spaced intervals throughout the day to maintain consistent drug levels.
Overdose
If you suspect an overdose of Ibuned, seek emergency medical help immediately by calling your local emergency number or poison control centre. NSAID overdose can cause nausea, vomiting, abdominal pain, drowsiness, headache, tinnitus (ringing in the ears), and in severe cases, gastrointestinal bleeding, metabolic acidosis, seizures, acute kidney injury, and loss of consciousness. There is no specific antidote for NSAID overdose; treatment is supportive and symptomatic.
In cases of significant overdose (more than 400 mg/kg), serious symptoms can develop including CNS depression, seizures, metabolic acidosis, and multi-organ failure. Activated charcoal may be administered within 1 hour of ingestion in a clinical setting. Gastric lavage is rarely needed. Supportive care includes maintaining airway, breathing, and circulation, monitoring electrolytes and acid-base balance, and managing complications as they arise. Haemodialysis is generally not effective for removing NSAIDs due to their high protein binding.
Always take Ibuned with or immediately after food to reduce the risk of gastrointestinal irritation. Swallow the film-coated tablet whole with a full glass of water. Do not crush, chew, or break the tablet, as the film coating is designed to protect the stomach lining. If you experience persistent stomach discomfort, consult your doctor about using a gastroprotective agent alongside your NSAID treatment.
What Are the Side Effects of Ibuned?
Like all medicines, Ibuned can cause side effects, although not everyone experiences them. The side effects of NSAIDs are well-characterised through decades of clinical use and post-marketing surveillance. Most side effects are dose-dependent and duration-dependent, which is why the lowest effective dose for the shortest necessary duration is always recommended. The following lists categorise side effects by how commonly they occur, based on data from clinical studies and pharmacovigilance databases.
Very Common
May affect more than 1 in 10 people
- Dyspepsia (heartburn, indigestion, stomach discomfort)
- Nausea
- Abdominal pain or cramping
Common
May affect up to 1 in 10 people
- Diarrhoea
- Vomiting
- Flatulence and bloating
- Constipation
- Headache
- Dizziness
- Drowsiness or fatigue
- Skin rash (non-serious)
- Mild fluid retention and peripheral oedema
Uncommon
May affect up to 1 in 100 people
- Gastric or duodenal ulceration
- Gastrointestinal bleeding (melaena, haematemesis)
- Elevated liver enzymes (ALT, AST)
- Urticaria (hives)
- Pruritus (itching)
- Tinnitus (ringing in the ears)
- Visual disturbances
- Increased blood pressure
- Mouth ulcers (stomatitis)
- Allergic rhinitis
Rare
May affect up to 1 in 1,000 people
- Gastrointestinal perforation (a medical emergency)
- Severe allergic reactions (anaphylaxis, angioedema)
- Asthma exacerbation or bronchospasm
- Hepatitis or jaundice
- Acute kidney injury (especially in dehydrated or elderly patients)
- Interstitial nephritis
- Haematological disorders (anaemia, leucopenia, thrombocytopenia)
- Severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis)
- Aseptic meningitis (particularly in patients with systemic lupus erythematosus)
- Heart failure exacerbation
Not Known
Frequency cannot be estimated from available data
- Myocardial infarction (heart attack) – risk increases with high doses and prolonged use
- Cerebrovascular accident (stroke) – risk increases with high doses and prolonged use
- DRESS syndrome (drug reaction with eosinophilia and systemic symptoms)
- Exacerbation of colitis or Crohn’s disease
Gastrointestinal Side Effects – Understanding the Risk
Gastrointestinal adverse effects are the most well-known and clinically significant risks associated with NSAID therapy. The mechanism involves inhibition of COX-1 in the gastric mucosa, which reduces the production of protective prostaglandins that maintain the stomach’s mucosal barrier. Without adequate prostaglandin levels, the stomach lining becomes more vulnerable to acid damage, leading to erosions, ulcers, and potentially bleeding or perforation.
Risk factors for NSAID-related GI complications include advanced age (over 65 years), history of peptic ulcer disease, concurrent use of oral corticosteroids, anticoagulants, or SSRIs, higher NSAID doses, longer duration of use, smoking, and alcohol consumption. If you have one or more of these risk factors, your doctor may prescribe a proton pump inhibitor (PPI) such as omeprazole, esomeprazole, or pantoprazole as gastroprotection alongside Ibuned.
Cardiovascular Side Effects
Large-scale meta-analyses and the Coxib and traditional NSAID Trialists’ (CNT) Collaboration have established that NSAIDs, when used at high doses for prolonged periods, are associated with a small but significant increase in the risk of major vascular events, including myocardial infarction and stroke. The absolute risk increase is estimated at approximately 3 additional major vascular events per 1,000 patient-years of NSAID use compared with non-use. This risk is highest in patients with pre-existing cardiovascular disease but is also present in those without known cardiovascular conditions.
To minimise cardiovascular risk, use Ibuned at the lowest effective dose for the shortest necessary duration. If you have established cardiovascular disease, discuss the risks and benefits with your doctor, who may recommend alternative analgesic strategies.
Contact your doctor or seek emergency medical care if you experience: black, tarry stools or blood in your stools; vomiting blood or material that looks like coffee grounds; chest pain, shortness of breath, or weakness on one side of the body; sudden severe abdominal pain; severe skin rash with blistering or peeling; or signs of a serious allergic reaction (swelling of face/throat, difficulty breathing). These may indicate serious complications requiring urgent treatment.
If you experience any side effects, including those not listed above, tell your doctor or pharmacist. You can also report suspected side effects to your national pharmacovigilance authority (e.g., the EMA in Europe, the FDA MedWatch program in the United States, or the MHRA Yellow Card Scheme in the United Kingdom).
How Should You Store Ibuned?
Proper storage of medications is essential to maintain their effectiveness and safety throughout their shelf life. Ibuned film-coated tablets should be stored according to the following guidelines:
- Temperature: Store at room temperature, below 25°C (77°F). Do not refrigerate or freeze. Avoid exposure to excessive heat, as high temperatures can degrade the active substance and compromise the integrity of the film coating.
- Moisture protection: Keep the tablets in their original blister packaging or container to protect them from moisture. Do not store in the bathroom or other humid environments, as moisture can affect the stability of the tablet.
- Light protection: Protect from direct sunlight. Store in the original carton when not in use.
- Children: Keep out of the sight and reach of children. Consider using a child-resistant storage location.
- Expiry date: Do not use Ibuned after the expiry date (EXP) stated on the blister or carton. The expiry date refers to the last day of that month.
Do not dispose of unused medicines via wastewater or household waste. Return unused or expired medications to your pharmacy for safe disposal. Proper medication disposal helps protect the environment and prevents accidental ingestion by children or pets.
What Does Ibuned Contain?
Active Substance
The active substance is ibuned. Each film-coated tablet contains 200 mg of ibuned. This is the component responsible for the therapeutic effects of the medication – pain relief, anti-inflammatory action, and fever reduction. The 200 mg strength is the standard dosing unit, and your doctor will advise how many tablets to take per dose based on your condition and individual needs.
Inactive Ingredients (Excipients)
In addition to the active substance, Ibuned tablets contain several inactive ingredients that are essential for the manufacturing process, stability, and quality of the finished product. These excipients do not contribute to the therapeutic effect but serve important pharmaceutical functions:
- Tablet core: Typically includes fillers (e.g., microcrystalline cellulose, lactose monohydrate), binders (e.g., povidone, croscarmellose sodium), lubricants (e.g., magnesium stearate), and disintegrants that help the tablet break down properly in the gastrointestinal tract for absorption.
- Film coating: The film coat is composed of polymers (e.g., hypromellose), plasticisers (e.g., macrogol/polyethylene glycol), and may include colourants (e.g., titanium dioxide, iron oxides). The coating protects the tablet from moisture, masks any unpleasant taste, and makes the tablet easier to swallow.
If you have known allergies or intolerances to any excipients (particularly lactose), check the patient information leaflet provided with your medication or consult your pharmacist before taking Ibuned.
Appearance
Ibuned is supplied as film-coated tablets. Film-coated tablets have a smooth, uniform surface that distinguishes them from uncoated or sugar-coated tablets. The specific colour, shape, and markings may vary depending on the manufacturer and market. Each tablet is designed to be swallowed whole with water.
Frequently Asked Questions About Ibuned
Ibuned is a non-steroidal anti-inflammatory drug (NSAID) prescribed for the relief of mild to moderate pain, including headaches, dental pain, musculoskeletal pain, menstrual cramps, and post-operative pain. It is also used to reduce inflammation and fever in conditions such as osteoarthritis, rheumatoid arthritis, and soft tissue injuries. It is available as 200 mg film-coated tablets and requires a prescription.
Take Ibuned with or immediately after food to reduce stomach irritation. Swallow the film-coated tablet whole with a full glass of water – do not crush, chew, or break it. The usual adult dose is 200 to 400 mg two to three times daily, depending on your doctor’s instructions. Always use the lowest effective dose for the shortest duration needed. Do not exceed the maximum daily dose prescribed by your doctor.
Yes, Ibuned can generally be taken alongside paracetamol (acetaminophen) if needed for additional pain relief, as they work through different mechanisms. Many clinical guidelines support alternating or combining NSAIDs with paracetamol for more effective pain management, particularly for post-operative or dental pain. However, you should not take Ibuned together with other NSAIDs (such as aspirin at anti-inflammatory doses, naproxen, or diclofenac), as this does not provide additional benefit and significantly increases the risk of gastrointestinal side effects.
Long-term use of any NSAID, including Ibuned, increases the risk of gastrointestinal, cardiovascular, and renal adverse effects. International guidelines consistently recommend using NSAIDs at the lowest effective dose for the shortest duration necessary. If you need long-term pain management for a chronic condition such as osteoarthritis or rheumatoid arthritis, your doctor should regularly review your treatment, monitor for side effects, and consider gastroprotection with a proton pump inhibitor. Non-pharmacological approaches (exercise, physiotherapy, weight management) should also be part of your overall treatment plan.
Ibuned should not be taken by people with a known allergy to the active substance or other NSAIDs, those with a history of NSAID-triggered asthma, urticaria (hives), or rhinitis, patients with active peptic ulcers or GI bleeding, those with severe heart, liver, or kidney failure, women in the third trimester of pregnancy, and people with active inflammatory bowel disease (Crohn’s or ulcerative colitis). Patients with uncontrolled hypertension or a history of cerebrovascular bleeding should also avoid Ibuned. Always discuss your full medical history with your doctor before starting any NSAID.
Alcohol consumption while taking Ibuned is generally not recommended, as both alcohol and NSAIDs irritate the gastric mucosa and increase the risk of gastrointestinal bleeding. If you do choose to drink, limit your intake to moderate levels and avoid taking Ibuned on an empty stomach. If you regularly consume more than moderate amounts of alcohol (more than 3 drinks per day), discuss alternative pain management strategies with your doctor, as the combined risk of GI bleeding becomes substantially higher.
References
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023. Available from: WHO Essential Medicines.
- European Medicines Agency (EMA). Assessment Report: Non-steroidal anti-inflammatory drugs (NSAIDs) and cardiovascular risk. 2023. Available from: EMA.
- National Institute for Health and Care Excellence (NICE). Clinical Knowledge Summary: NSAIDs – prescribing issues. Last updated 2024. Available from: NICE CKS.
- British National Formulary (BNF). Non-steroidal anti-inflammatory drugs. 2025. Available from: BNF.
- Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials (Coxib and traditional NSAID Trialists’ Collaboration). Lancet. 2013;382(9894):769–779. doi:10.1016/S0140-6736(13)60900-9.
- Lanas A, Chan FKL. Peptic ulcer disease. Lancet. 2017;390(10094):613–624. doi:10.1016/S0140-6736(16)32404-7.
- U.S. Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA strengthens warning that non-aspirin NSAIDs can cause heart attacks or strokes. 2015 (updated 2023). Available from: FDA Drug Safety.
- Derry S, Moore RA, Rabbie R. Topical NSAIDs for acute musculoskeletal pain in adults. Cochrane Database Syst Rev. 2015;(6):CD007402. doi:10.1002/14651858.CD007402.pub3.
- Marjoribanks J, Ayeleke RO, Farquhar C, Proctor M. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev. 2015;(7):CD001751. doi:10.1002/14651858.CD001751.pub3.
- Ungprasert P, Cheungpasitporn W, Crowson CS, Matteson EL. Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: A systematic review and meta-analysis. Eur J Intern Med. 2015;26(4):285–291. doi:10.1016/j.ejim.2015.03.008.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in clinical pharmacology, pain medicine, and rheumatology.
Medical Content
iMedic Pharmacology Editorial Team – specialist physicians in clinical pharmacology with expertise in NSAID therapeutics and drug safety
Medical Review
iMedic Medical Review Board – independent panel verifying accuracy against EMA SmPC, FDA label, NICE, and BNF guidelines
Pharmacology Review
iMedic Clinical Pharmacology Team – specialists in drug interactions, pharmacokinetics, and medication safety
Accessibility & SEO
iMedic Digital Health Team – ensuring WCAG 2.2 AAA compliance and optimal search visibility
All content follows the GRADE evidence framework and is reviewed according to international medical guidelines. iMedic receives no commercial funding from pharmaceutical companies.